Shimon I, Melmed S
Department of Medicine, Cedars-Sinai Research Institute, UCLA School of Medicine 90048, USA.
J Endocrinol. 1997 Oct;155 Suppl 1:S3-6; discussion S7-8.
This new generation of SRIF analogs offer exciting opportunities to improve hormone hypersecretion in patients with GH- and TSH-secreting pituitary adenomas and possibly even in patients harboring prolactinomas and non-functioning tumors. Future development of novel analogs with improved affinity for both SSTR2 and SSTR5 may have even greater potency to suppress pituitary hormone hypersecretion and block adenoma growth.
新一代生长抑素类似物为改善生长激素分泌型和促甲状腺激素分泌型垂体腺瘤患者甚至可能是催乳素瘤和无功能肿瘤患者的激素分泌过多提供了令人兴奋的机会。未来开发对生长抑素受体2和生长抑素受体5具有更高亲和力的新型类似物可能具有更大的抑制垂体激素分泌过多和阻止腺瘤生长的效力。